Health & Biotech
NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II and is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
10 at 10: These ASX stocks are on the hunt this morning
Health & Biotech
Bondi backpackers rejoice! Recce may have a gonorrhoea cure
News
The pandemic could make companies think twice about manufacturing offshore
News
10 at 10: These ASX stocks are clearing the hurdles this morning
Health & Biotech
Check up: The COVID-crisis strikes leaving just 9 stocks in the black
News
Rise and Shine: What you need to know before the ASX opens
News
Dementia sufferers in Australia will hit 1 million, can these small caps come up with a treatment?
Health & Biotech
Health: Impedimed shares dip as investors sell the hidden bad news
Health & Biotech
Brain health is complicated, but these ASX small caps are trying to keep it in shape
Health & Biotech
Asia is where health investors are making money this year
Health & Biotech
Check out these 5 exciting ASX microcaps solving the world’s biggest health issues
Health & Biotech
Health: Opthea’s taking its successful anti-AMD drug to a 1,320 patient phase III trial; raises $50m
Health & Biotech
Biotech exec pay — are they delivering returns that equal their pay packets?
Health & Biotech
Building a sustainable biotech sector in WA
Health & Biotech
Health: Actinogen recovers some hope from Xanamem wreckage
News
Rise & Shine: What you need to know before the ASX opens
News